In the absence of head-to-head studies, oncologists are looking across pivotal trials and are encouraged by Itovebi's safety and efficacy versus Piqray.

The patient died from complications linked to a rare hyperinflammatory syndrome associated with exposure to high doses of the AAV therapy delivery vehicle.

Patients with PTEN-deficient prostate cancer showed improvement in progression-free survival on Truqap plus standard therapy compared to standard therapy alone.

As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Jazz Pharmaceuticals' Ziihera (zanidatamab) as a treatment for advanced HER2-positive biliary tract cancer.

NEW YORK – Neuron23 this week detailed the design of its global Phase II trial, dubbed NEULARK, in which it is investigating a precision treatment strategy in early Parkinson's disease. Within the ...

NEW YORK – Aptose Biosciences on Wednesday said it began testing its multi-kinase inhibitor tuspetinib with azacitidine and AbbVie and Genentech's Venclexta (venetoclax) in a Phase I/II trial as a ...